Abstract:Cerebral hypoglycemia/hypometabolism is associated with Alzheimer's disease (AD) and is routinely used to assist clinical diagnosis of AD by brain imaging. However, whether cerebral hypoglycemia/hypometabolism contributes to the development of AD or is a response of reduced neuronal activity remains unclear. To investigate the causal relationship, we cultured the differentiated N2a neuroblastoma cells in glucose/pyruvate-deficient media (GDM). Shortly after the N2a cells cultured in the GDM, the mitochondria membrane potential was reduced and the AMP-activated-proteinkinase (AMPK), an energy sensor, was activated. Treatment of GDM not only increased the levels of tau phosphorylation at Ser(262) and Ser(396), but also increased the levels of active forms of GSK3α and GSK3β, two known kinases for tau phosphorylation, of the N2a cells. The levels of activated Akt, a mediator downstream to AMPK and upstream to GSK3α/β, were reduced by the GDM treatment. The effect of hypoglycemia was further examined in vivo by intracerebroventricular (icv) injection of streptozotocin (STZ) to the Wistar rats. STZ selectively injuries glucose transporter type 2-bearing cells which are primarily astrocytes in the rat brain, hence, interrupts glucose transportation from blood vessel to neuron. STZicv injection induced energy crisis in the brain regions surrounding the ventricles, as indicated by higher pAMPK levels in the hippocampus, but not cortex far away from the ventricles. STZ-icv treatment increased the levels of phosphorylated tau and activated GSK3β, but decreased the levels of activated Akt in the hippocampus. The hippocampus-dependent spatial learning and memory was impaired by the STZ-icv treatment. In conclusion, our works suggest that hypoglycemia enhances the AMPK-Akt-GSK3 pathway and leads to tau hyperphosphorylation.

Glycogen synthase kinase-3 regulates production of amyloid-β peptides and tau phosphorylation in diabetic rat brain.

Disturbance of Gsk-3 and Pp-2a Induced Tau Hyperphosphorylation in Diabetic Rat Brain

Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease

Effects Of Streptozotocin-Induced Diabetes On Tau Phosphorylation In The Rat Brain

Expression Changes of Growth-Associated Protein-43 (Gap-43) and Mitogen-Activated Protein Kinase Phosphatase-1 (Mkp-1) and in Hippocampus of Streptozotocin-Induced Diabetic Cognitive Impairment Rats

Inhibiting PI3K leads to glucose metabolism disturbance in default mode network

Deregulation of Brain Insulin Signaling in Alzheimer’s Disease

[Alteration of Beta-Amyloid and Glutamate Transporter in the Brain of Diabetes Rats and the Underlying Mechanism].

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

The Disturbance of Hippocampal Camkii/Pka/Pkc Phosphorylation in Early Experimental Diabetes Mellitus

The Research on the Relationship of RAGE, LRP-1, and Aβ Accumulation in the Hippocampus, Prefrontal Lobe, and Amygdala of STZ-Induced Diabetic Rats

β-Amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3

Targeting glycogen synthase kinase-3 β for Alzheimer's disease: Recent advances and future Prospects

Autophagy-Lysosome Dysfunction Is Involved In A Beta Deposition In Stz-Induced Diabetic Rats

Hypoglycemia induces tau hyperphosphorylation

Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory.

Chronic hyperglycemia induced via the heterozygous knockout of Pdx1 worsens neuropathological lesion in an Alzheimer mouse model

Streptozotocin-induced diabetes increases amyloid plaque deposition in AD transgenic mice through modulating AGEs/RAGE/NF-κB pathway

Molecular alteration of the proteasome contributes to AD-like pathology in the brain of HFD-STZ diabetic rats

Targeting Glycogen Synthase Kinase-3Β for Alzheimer's Disease: Recent Advances and Future Prospects

GSK-3 in Neurodegenerative Diseases